|
1
|
Boyle P and Ferlay J: Cancer incidence and
mortality in Europe 2004. Ann Oncol. 16:481–488. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Epstein JI, Allsbrook WC Jr, Amin MB and
Egevad LL: ISUP grading committee. The 2005 International Society
of Urologic Pathology (ISUP) consensus conference on Gleason
grading of prostatic carcinoma. Am J Surg Pathol. 29:1228–1242.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hemminki K: Familial risk and familial
survival in prostate cancer. World J Urol. 30:143–148. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leitzmann MF and Rohrmann S: Risk factors
for the onset of prostatic cancer: Age, location and behavioral
correlates. Clin Epidemiol. 4:1–11. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Oliver SE, May MT and Gunnell D:
International trends in prostate-cancer mortality in the ‘PSA-ERA’.
Int J Cancer. 92:893–898. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ilic D, O'Connor D, Green S and Wilt T:
Screening for prostate cancer: A Cochrane systematic review. Cancer
Causes Control. 18:279–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Roobol MJ, Roobol DW and Schröder FH: Is
additional testing necessary in men with prostate-specific antigen
levels of 1.0 ng/ml or less in a population-based screening
setting? (ERSPC, section Rotterdam). Urology. 65:343–346. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heenan SD: Magnetic resonance imaging in
prostate cancer. Prostate Cancer Prostatic Dis. 7:282–288. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Scher HI, Halabi S, Tannock I, et al:
Design and end points of clinical trials for patients with
progressive prostate cancer and castrate levels of testosterone:
Recommendations of the Prostate Cancer Clinical Trials Working
Group. J Clin Oncol. 26:1148–1159. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharma P, Karunanithi S, Singh Dhull V, et
al: Prostate cancer with lytic bone metastases:
18F-fluorodeoxyglucose positron emission tomography-computed
tomography for diagnosis and monitoring response to medical
castration therapy. Indian J Nucl Med. 28:178–179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Apolo AB, Pandit-Taskar N and Morris MJ:
Novel tracers and their development for the imaging of metastatic
prostate cancer. J Nucl Med. 49:2031–2041. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jadvar H: Molecular imaging of prostate
cancer: PET radiotracers. AJR Am J Roentgenol. 199:278–291. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jadvar H: Molecular imaging of prostate
cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol. 6:317–323.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
European Association of Urology.
Guidelines on Prostate Cancer. http://uroweb.org/wp-content/uploads/09-Prostate-Cancer_LR.pdfAccessed.
June 15–2015
|
|
16
|
Cookson MS, Aus G, Burnett AL, et al:
Variation in the definition of biochemical recurrence in patients
treated for localized prostate cancer: The American urological
association prostate guidelines for localized prostate cancer
update panel report and recommendations for a standard in the
reporting of surgical outcomes. J Urol. 177:540–545. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Howlader N, Noone AM, Krapcho M, Garshell
J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,
et al: SEER Cancer Statistics Review, 1975–2012. Bethesda, MD:
National Cancer Institute. http://seer.cancer.gov/csr/1975_2012/Accessed.
December 02–2013
|
|
18
|
Jadvar H, Desai B, Ji L, et al:
Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection
of occult metastatic disease in biochemical recurrence of prostate
cancer. Clin Nucl Med. 37:637–643. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gillies RJ, Robey I and Gatenby RA: Causes
and consequences of increased glucose metabolism of cancers. J Nucl
Med. 49(Suppl 2): 24S–42S. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Smith TA: Mammalian hexokinases and their
abnormal expression in cancer. Br J Biomed Sci. 57:170–178.
2000.PubMed/NCBI
|
|
21
|
Effert P, Beniers AJ, Tamimi Y, Handt S
and Jakse G: Expression of glucose transporter 1 (GLUT-1) in cell
lines and clinical specimen from human prostate adenocarcinoma.
Anticancer Res. 24:3057–3063. 2004.PubMed/NCBI
|
|
22
|
Stewart GD, Gray K, Pennington CJ, et al:
Analysis of hypoxia-associated gene expression in prostate cancer:
Lysyl oxidase and glucose transporter-1 expression correlate with
Gleason score. Oncol Rep. 20:1561–1567. 2008.PubMed/NCBI
|
|
23
|
Kukuk D, Reischl G, Raguin O, et al:
Assessment of PET tracer uptake in hormone-independent and
hormone-dependent xenograft prostate cancer mouse models. J Nucl
Med. 52:1654–1663. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jadvar H, Ye W, Groshen S and Conti PS:
[F-18]-fl [F-18]-Fluorodeoxyglucose PET-CT of the normal prostate
gland. Ann Nucl Med. 22:787–793. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shiiba M, Ishihara K, Kimura G, et al:
Evaluation of primary prostate cancer using 11C-methionine-PET/CT
and 18F-FDG-PET/CT. Ann Nucl Med. 26:138–145. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Minamimoto R, Uemura H, Sano F, Terao H,
Nagashima Y, Yamanaka S, Shizukuishi K, Tateishi U, Kubota Y and
Inoue T: The potential of FDG PET/CT for detecting prostate cancer
in patients with an elevated serum PSA level. Ann Nucl Med.
25:21–27. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schöder H, Hermann K, Gönen M, Hricak H,
Eberhard S, Scardino P, Scher HI and Larson SM: 2-[18F]
fluoro-2-deoxyglucose positron emission tomography for detection of
disease in patients with prostate-specific antigen relapse after
radical prostatectomy. Clin Cancer Res. 11:4761–4769. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chang CH, Wu HC, Tsai JJ, et al: Detecting
metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron
emission tomography in patients with prostate specific antigen
relapse after treatment for localized prostate cancer. Urol Int.
70:311–315. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jadvar H, Desai B and Quinn D: Treatment
response assessment of metastatic prostate cancer with FDG PET/CT.
J Nucl Med. 52(Suppl 1): 431P2011.
|
|
30
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wahl RL, Jacene H, Kasamon Y and Lodge MA:
From RECIST to PERCIST: Evolving Considerations for PET response
criteria in solid tumors. J Nucl Med. 50:122S–150S. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hillner BE, Siegel BA, Shields AF, et al:
Relationship between cancer type and impact of PET and PET/CT on
intended management: Findings of the national oncologic PET
registry. J Nucl Med. 49:1928–1935. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hwang I, Chong A, Jung SI, et al: Is
further evaluation needed for incidental focal uptake in the
prostate in 18-fluoro-2-deoxyglucose positron emission
tomography-computed tomography images? Ann Nucl Med. 27:140–145.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Minamimoto R, Senda M, Jinnouchi S, et al:
The current status of an FDG-PET cancer screening program in Japan,
based on a 4-year (2006–2009) nationwide survey. Ann Nucl Med.
27:46–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wright JL, Lin DW and Stanford JL: The
effect of demographic and clinical factors on the relationship
between BMI and PSA levels. Prostate. 71:1631–1637. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Koochekpour S, Majumdar S, Azabdaftari G,
et al: Serum glutamate levels correlate with Gleason score and
glutamate blockade decreases proliferation, migration and invasion
and induces apoptosis in prostate cancer cells. Clin Cancer Res.
18:5888–5901. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bartoletti R, Meliani E, Bongini A, Magno
C and Cai T: Fluorodeoxyglucose positron emission tomography may
aid the diagnosis of aggressive primary prostate cancer: A case
series study. Oncol Lett. 7:381–386. 2014.PubMed/NCBI
|
|
38
|
Tombal B and Lecouvet F: Modern detection
of prostate cancer's bone metastasis: Is the Bone Scan Era Over?
Adv Urol. 2012:8931932012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mulders PF and Schalken JA: Measuring
therapeutic efficacy in the changing paradigm of castrate-resistant
prostate cancer. Prostate Cancer Prostatic Dis. 12:241–246. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ryan CJ, Shah S, Efstathiou E, et al:
Phase II study of abiraterone acetate in chemotherapy-naive
metastatic castration-resistant prostate cancer displaying bone
flare discordant with serologic response. Clin Cancer Res.
17:4854–4861. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rabbani SA, Gladu J, Harakidas P, Jamison
B and Goltzman D: Over-production of parathyroid hormone-related
peptide results in increased osteolytic skeletal metastasis by
prostate cancer cells in vivo. Int J Cancer. 80:257–264. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Oyama N, Akino H, Suzuki Y, et al:
Prognostic value of 2-deoxy-2-[F-18] fluoro-D-glucose positron
emission tomography imaging for patients with prostate cancer. Mol
Imaging Biol. 4:99–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meirelles GS, Schöder H, Ravizzini GC, et
al: Prognostic value of baseline [18F] fluorodeoxyglucose positron
emission tomography and 99mTc-MDP bone scan in progressing prostate
cancer. Clin Cancer Res. 16:6093–6099. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Jadvar H, Xiankui L, Shahinian A, et al:
Glucose metabolism of human prostate cancer mouse xenografts. Mol
Imaging. 4:91–97. 2005.PubMed/NCBI
|
|
45
|
Morris MJ, Akhurst T, Osman I, et al:
Fluorinated deoxyglucose positron emission tomography imaging in
progressive metastatic prostate cancer. Urology. 59:913–918. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Jadvar H, Desai B, Ji L, Conti PS, Dorff
TB, Groshen SG, Pinski JK and Quinn DI: Baseline 18F-FDG PET/CT
parameters as imaging biomarkers of overall survival in
castrate-resistant metastatic prostate cancer. J Nucl Med.
54:1195–1201. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
El Fakhri G, Surti S, Trott CM,
Scheuermann J and Karp JS: Improvement in lesion detection with
whole-body oncologic time-of-flight PET. J Nucl Med. 52:347–353.
2011. View Article : Google Scholar : PubMed/NCBI
|
